NEUROCRINE BIOSCIENCES INC Gain (Loss) on Disposition of Assets for Financial Service Operations
NEUROCRINE BIOSCIENCES INC (NBIX) reported Gain (Loss) on Disposition of Assets for Financial Service Operations of $760.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnSalesOfAssets · last filed 2019-02-08
- NEUROCRINE BIOSCIENCES INC gain (loss) on disposition of assets for financial service operations for the quarter ending 2018-06-30 was $147.00K, a 83.31% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC gain (loss) on disposition of assets for financial service operations for the quarter ending 2018-03-31 was $201.00K, a 77.13% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC gain (loss) on disposition of assets for financial service operations for the quarter ending 2017-12-31 was $156.00K, a 81.92% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC gain (loss) on disposition of assets for financial service operations for the quarter ending 2017-09-30 was $188.00K, a 77.73% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC gain (loss) on disposition of assets for financial service operations for fiscal 2018 was $760.00K, a 63.88% decline from fiscal 2017.
- NEUROCRINE BIOSCIENCES INC gain (loss) on disposition of assets for financial service operations for fiscal 2017 was $2.10M, a 38.68% decline from fiscal 2016.
- NEUROCRINE BIOSCIENCES INC gain (loss) on disposition of assets for financial service operations for fiscal 2016 was $3.43M, a 2.91% increase from fiscal 2015.
- NEUROCRINE BIOSCIENCES INC gain (loss) on disposition of assets for financial service operations for fiscal 2015 was $3.33M, a 3.48% increase from fiscal 2014.
| Period end | Gain (Loss) on Disposition of Assets for Financial Service Operations 3 month | Gain (Loss) on Disposition of Assets for Financial Service Operations 6 month | Gain (Loss) on Disposition of Assets for Financial Service Operations 6 month as first filed | Gain (Loss) on Disposition of Assets for Financial Service Operations 9 month | Gain (Loss) on Disposition of Assets for Financial Service Operations 9 month as first filed | Gain (Loss) on Disposition of Assets for Financial Service Operations 12 month |
|---|---|---|---|---|---|---|
| 2018-12-31 | $760.00K 10-K · filed 2019-02-08 | |||||
| 2018-06-30 | $147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $348.00K 10-Q · filed 2018-07-31 | $504.00K derived: sum of 3 quarters · filed 2019-02-08 | $692.00K derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2018-03-31 | $201.00K 10-Q · filed 2018-04-30 | $357.00K derived: sum of 2 quarters · filed 2019-02-08 | $545.00K derived: sum of 3 quarters · filed 2019-02-08 | $1.43M derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2017-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $344.00K derived: sum of 2 quarters · filed 2019-02-08 | $1.23M derived: sum of 3 quarters · filed 2019-02-08 | $2.10M 10-K · filed 2019-02-08 | ||
| 2017-09-30 | $188.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $1.07M derived: sum of 2 quarters · filed 2018-07-31 | $1.95M 10-Q · filed 2017-11-01 | $2.81M derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2017-06-30 | $881.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $1.76M 10-Q · filed 2018-07-31 | $2.62M derived: sum of 3 quarters · filed 2019-02-08 | $3.47M derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2017-03-31 | $879.00K 10-Q · filed 2018-04-30 | $1.74M derived: sum of 2 quarters · filed 2019-02-08 | $2.59M derived: sum of 3 quarters · filed 2019-02-08 | $3.45M derived: sum of 4 quarters · filed 2019-02-08 | ||
| 2016-12-31 | $863.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $1.71M derived: sum of 2 quarters · filed 2019-02-08 | $2.58M derived: sum of 3 quarters · filed 2019-02-08 | $3.43M 10-K · filed 2019-02-08 | ||
| 2016-09-30 | $844.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $1.71M derived: sum of 2 quarters · filed 2017-11-01 | $2.57M 10-Q · filed 2017-11-01 | $3.41M derived: sum of 4 quarters · filed 2018-02-13 | ||
| 2016-06-30 | $868.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $1.72M 10-Q · filed 2017-08-03 | $2.56M derived: sum of 3 quarters · filed 2018-02-13 | $3.39M derived: sum of 4 quarters · filed 2018-02-13 | ||
| 2016-03-31 | $856.00K 10-Q · filed 2017-05-09 | $1.69M derived: sum of 2 quarters · filed 2018-02-13 | $2.52M derived: sum of 3 quarters · filed 2018-02-13 | $3.35M derived: sum of 4 quarters · filed 2018-02-13 | ||
| 2015-12-31 | $838.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $1.67M derived: sum of 2 quarters · filed 2018-02-13 | $2.50M derived: sum of 3 quarters · filed 2018-02-13 | $3.33M 10-K · filed 2018-02-13 | ||
| 2015-09-30 | $828.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $1.66M derived: sum of 2 quarters · filed 2016-11-02 | $2.50M 10-Q · filed 2016-11-02 | $3.31M derived: sum of 4 quarters · filed 2017-02-14 | ||
| 2015-06-30 | $829.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $1.67M 10-Q · filed 2016-08-03 | $2.48M derived: sum of 3 quarters · filed 2017-02-14 | $3.29M derived: sum of 4 quarters · filed 2017-02-14 | ||
| 2015-03-31 | $839.00K 10-Q · filed 2016-05-05 | $1.65M derived: sum of 2 quarters · filed 2017-02-14 | $2.46M derived: sum of 3 quarters · filed 2017-02-14 | $3.27M derived: sum of 4 quarters · filed 2017-02-14 | ||
| 2014-12-31 | $812.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $1.62M derived: sum of 2 quarters · filed 2017-02-14 | $2.43M derived: sum of 3 quarters · filed 2017-02-14 | $3.22M 10-K · filed 2017-02-14 | ||
| 2014-09-30 | $806.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $1.62M derived: sum of 2 quarters · filed 2015-10-29 | $2.41M 10-Q · filed 2015-10-29 | $3.20M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2014-06-30 | $810.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-29 | $1.60M 10-Q · filed 2015-07-29 | $2.39M derived: sum of 3 quarters · filed 2016-02-11 | $3.18M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2014-03-31 | $794.00K 10-Q · filed 2015-04-30 | $1.58M derived: sum of 2 quarters · filed 2016-02-11 | $2.37M derived: sum of 3 quarters · filed 2016-02-11 | $3.17M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2013-12-31 | $788.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $1.57M derived: sum of 2 quarters · filed 2016-02-11 | $2.38M derived: sum of 3 quarters · filed 2016-02-11 | $3.17M 10-K · filed 2016-02-11 | ||
| 2013-09-30 | $787.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $1.59M derived: sum of 2 quarters · filed 2014-11-04 | $2.38M 10-Q · filed 2014-11-04 | $3.15M derived: sum of 4 quarters · filed 2015-02-09 | ||
| 2013-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $1.59M 10-Q · filed 2014-08-06 | $2.37M derived: sum of 3 quarters · filed 2015-02-09 | $3.13M derived: sum of 4 quarters · filed 2015-02-09 | ||
| 2013-03-31 | $795.00K 10-Q · filed 2014-05-01 | $1.57M derived: sum of 2 quarters · filed 2015-02-09 | $2.33M derived: sum of 3 quarters · filed 2015-02-09 | $3.09M derived: sum of 4 quarters · filed 2015-02-09 | ||
| 2012-12-31 | $773.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | $1.53M derived: sum of 2 quarters · filed 2015-02-09 | $2.29M derived: sum of 3 quarters · filed 2015-02-09 | $3.07M 10-K · filed 2015-02-09 | ||
| 2012-09-30 | $759.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $1.52M derived: sum of 2 quarters · filed 2013-10-29 | $2.30M 10-Q · filed 2013-10-29 | $3.10M derived: sum of 4 quarters · filed 2013-10-29 | ||
| 2012-06-30 | $759.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | $1.54M 10-Q · filed 2013-07-26 | $2.34M derived: sum of 3 quarters · filed 2013-07-26 | $3.17M derived: sum of 4 quarters · filed 2013-07-26 | ||
| 2012-03-31 | $783.00K 10-Q · filed 2013-05-02 | $1.58M derived: sum of 2 quarters · filed 2013-05-02 | $2.41M derived: sum of 3 quarters · filed 2013-05-02 | $3.16M derived: sum of 4 quarters · filed 2013-05-02 | ||
| 2011-12-31 | $802.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $1.62M derived: sum of 2 quarters · filed 2013-02-08 | $2.38M derived: sum of 3 quarters · filed 2013-02-08 | $3.19M 10-K · filed 2013-02-08 | ||
| 2011-09-30 | $822.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | $1.58M derived: sum of 2 quarters · filed 2012-10-31 | $2.39M 10-Q · filed 2012-10-31 | $184.00K 10-Q · filed 2011-10-31 | $5.35M derived: sum of 4 quarters · filed 2013-02-08 | |
| 2011-06-30 | $755.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-31 | $1.57M 10-Q · filed 2012-07-31 | $98.00K 10-Q · filed 2011-07-29 | $4.53M derived: sum of 3 quarters · filed 2013-02-08 | $4.56M derived: sum of 4 quarters · filed 2013-02-08 | |
| 2011-03-31 | $816.00K 10-Q · filed 2012-05-02 | $3.77M derived: sum of 2 quarters · filed 2013-02-08 | $3.81M derived: sum of 3 quarters · filed 2013-02-08 | |||
| 2010-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $2.99M derived: sum of 2 quarters · filed 2013-02-08 | $3.16M 10-K · filed 2013-02-08 | |||
| 2010-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $202.00K 10-Q · filed 2011-10-31 | ||||
| 2010-06-30 | $168.00K 10-Q · filed 2011-07-29 | |||||
| 2009-12-31 | $3.63M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |